A Study of Participants With Non-Valvular Atrial Fibrillation (NVAF) Treated or Untreated With Oral Anticoagulant in the National Cerebral and Cardiovascular Center (NCVC) in Japan

Bristol-Myers Squibb11,776 enrolled

Overview

The purpose of this observational study is to understand real-world oral anticoagulants (OAC) (warfarin, apixaban, dabigatran, edoxaban and rivaroxaban) usage for non-valvular atrial fibrillation (NVAF) patients.

Study Type

OBSERVATIONAL

Enrollment

11,776

Conditions

Non-Valvular Atrial Fibrillation (NVAF)

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: • Participants received medical treatment for NVAF between 10-Jan-2012 and 31-Aug-2020. Exclusion Criteria: * Had no data of serum creatinine in the participant's medical records * Had no data of body weight in the participant's medical records * Were given oral anticoagulant (OAC) for treatment of diseases other than atrial fibrillation (AF) Other protocol-defined inclusion/exclusion criteria apply.

Locations (1)

Local Institution

Tokyo, Japan

Outcomes

Primary Outcomes

Specialization of the treating physician

Time frame: At Baseline

Distribution of socio-demographic characteristics of NVAF participants: Age group

Time frame: At Baseline

Distribution of socio-demographic characteristics of NVAF participants: Gender

Time frame: At Baseline

Distribution of socio-demographic characteristics of NVAF participants: Body weight

Time frame: At Baseline

Distribution of socio-demographic characteristics of NVAF participants: Height

Time frame: At Baseline

Distribution of socio-demographic characteristics of NVAF participants: Body mass index (BMI)

Time frame: At Baseline

Distribution of outcomes of NVAF participants: Drinking information

Time frame: At Baseline

Distribution of outcomes of NVAF participants: Smoking information

Time frame: At Baseline

Distribution of outcomes of NVAF participants: Internal medical device information

Time frame: At Baseline

Distribution of outcomes of NVAF participants: Degree of life freedom

Time frame: At Baseline

Distribution of outcomes of NVAF participants: Hospitalization/outpatient status

Time frame: At Baseline

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Distribution of outcomes of NVAF participants: Systolic and diastolic blood pressure

Time frame: At Baseline

Distribution of outcomes of NVAF participants: Pulse rate

Time frame: At Baseline

Distribution of clinical characteristics of NVAF participants: Risk factors for stroke

Time frame: At Baseline

Distribution of clinical characteristics of NVAF participants: Risk factors for bleeding

Time frame: At Baseline

Distribution of clinical characteristics of NVAF participants: Comorbidities

Time frame: At Baseline

Distribution of outcomes of NVAF participants: OAC prescription and administration status

Time frame: At Baseline

Distribution of medication prescribed during baseline: angiotensin-converting enzyme inhibitor (ACE)

Time frame: At Baseline

Distribution of medication prescribed during baseline: angiotensin-receptor blocker (ARB)

Time frame: At Baseline

Distribution of medication prescribed during baseline: calcium antagonist

Time frame: At Baseline

Distribution of medication prescribed during baseline: Antiarrhythmic drug

Time frame: At Baseline

Distribution of medication prescribed during baseline: Statin

Time frame: At Baseline

Distribution of medication prescribed during baseline: proton pump inhibitor (PPI)

Time frame: At Baseline

Distribution of medication prescribed during baseline: H2-receptor antagonist

Time frame: At Baseline

Distribution of medication prescribed during baseline: aspirin

Time frame: At Baseline

Distribution of medication prescribed during baseline: P2Y12 inhibitor

Time frame: At Baseline

Distribution of medication prescribed during baseline: Other antiplatelet drugs

Time frame: At Baseline

Distribution of medication prescribed during baseline: Other anticoagulants

Time frame: At Baseline

Distribution of medication prescribed during baseline: P-glycoprotein inhibitor

Time frame: At Baseline